15.23

1.60% 0.24

After Hours: 14.93 -0.30 -1.97%

Design Therapeutics Inc (DSGN)

Overview News Price History Option Chain Financials Discussions Forecast

Design Therapeutics Inc stock is traded at $15.23, with a volume of 408.61K. It is up +1.60% in the last 24 hours and up +29.29% over the past month. Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Previous Close:

$14.99

Open:

$14.91

24h Volume:

408.61K

Relative Volume:

0.51

Market Cap:

$953.12M

Revenue:

Net Income/Loss:

$-69.71M

P/E Ratio:

-12.76

EPS:

-1.1935

Net Cash Flow:

$-54.12M

1W Performance:

+0.86%

1M Performance:

+29.29%

6M Performance:

+43.68%

1Y Performance:

+189.54%

1-Day Range:

$14.64

$15.47

1-Week Range:

$14.64

$16.12

52-Week Range:

$4.92

$17.25

Design Therapeutics Inc Stock (DSGN) Company Profile

Name

Design Therapeutics Inc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

858-293-4900

Address

6005 HIDDEN VALLEY ROAD, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

DSGN's Discussions on Twitter

Compare DSGN vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DSGN Design Therapeutics Inc	15.23	973.77M	0	-69.71M	-54.12M	-1.1935
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	Jefferies	Buy
Jan-07-26	Initiated	Oppenheimer	Outperform
Dec-03-25	Initiated	Craig Hallum	Buy
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-20-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-07-24	Upgrade	Piper Sandler	Neutral → Overweight
Nov-14-23	Downgrade	Piper Sandler	Overweight → Neutral
Aug-15-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-15-23	Downgrade	SVB Securities	Outperform → Market Perform
Aug-15-23	Downgrade	Wedbush	Outperform → Neutral
May-04-23	Upgrade	Goldman	Sell → Neutral
Jun-10-22	Initiated	Wedbush	Outperform
May-02-22	Initiated	RBC Capital Mkts	Outperform
Jan-19-22	Initiated	Goldman	Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-20-21	Initiated	Piper Sandler	Overweight
Apr-20-21	Initiated	SVB Leerink	Outperform

View All

Design Therapeutics Inc Stock (DSGN) Latest News

Aug 16, 2026

DSGN Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesFiscal Year Earnings - Vinanet

Aug 16, 2026

Aug 14, 2026

DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.06% Stock GainMid-Term Outlook - Vinanet

Aug 14, 2026

Design Therapeutics Stock Price Forecast. Should You Buy DSGN? - StockInvest.us

Aug 14, 2026

Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares - Stock Titan

Aug 14, 2026

Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake - Stock Titan

Aug 14, 2026

Aug 12, 2026